EGFR-TKI-话题@MedSci

#EGFR-TKI#

60篇内容 | 2951人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1383073, encodeId=5c9413830e328, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象, objectType=article, longId=160819, objectId=e400160819af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e400160819af, replyNumber=0, likeNumber=65, createdTime=2019-02-24, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e400160819af, moduleTitle=Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e400160819af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383072, encodeId=a2e913830e22e, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, objectType=article, longId=159801, objectId=957315980197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=957315980197, replyNumber=0, likeNumber=64, createdTime=2019-02-13, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=957315980197, moduleTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=957315980197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383071, encodeId=659613830e175, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, objectType=article, longId=147673, objectId=4a4a14e6733c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4a14e6733c, replyNumber=0, likeNumber=85, createdTime=2018-08-31, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4a14e6733c, moduleTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4a14e6733c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383070, encodeId=f5dc13830e096, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, objectType=article, longId=144828, objectId=bdde144828d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdde144828d7, replyNumber=0, likeNumber=98, createdTime=2018-07-22, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdde144828d7, moduleTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdde144828d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383069, encodeId=573e13830698a, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=三代EGFR-TKI艾维替尼提交国内上市申请, objectType=article, longId=141444, objectId=18441414444a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18441414444a, replyNumber=0, likeNumber=62, createdTime=2018-06-25, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18441414444a, moduleTitle=三代EGFR-TKI艾维替尼提交国内上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18441414444a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383068, encodeId=0af3138306843, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, objectType=article, longId=134084, objectId=2a11134084c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a11134084c4, replyNumber=0, likeNumber=109, createdTime=2018-04-04, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a11134084c4, moduleTitle=JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a11134084c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383067, encodeId=74a4138306e5c, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, objectType=article, longId=124734, objectId=05dd124e34e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05dd124e34e0, replyNumber=0, likeNumber=153, createdTime=2017-12-28, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05dd124e34e0, moduleTitle=N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05dd124e34e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383066, encodeId=e8b6138306623, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批, objectType=article, longId=120579, objectId=4e541205e950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e541205e950, replyNumber=0, likeNumber=90, createdTime=2017-11-19, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e541205e950, moduleTitle=阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e541205e950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383065, encodeId=21f3138306542, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略, objectType=article, longId=119408, objectId=f1bc1194081a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc1194081a, replyNumber=0, likeNumber=72, createdTime=2017-11-11, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc1194081a, moduleTitle=陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc1194081a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383064, encodeId=7ba7138306459, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵, objectType=article, longId=119396, objectId=8df0119396d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8df0119396d1, replyNumber=0, likeNumber=87, createdTime=2017-11-11, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8df0119396d1, moduleTitle=刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8df0119396d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383063, encodeId=e73813830635f, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, objectType=article, longId=114074, objectId=7e4c1140e4f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4c1140e4f6, replyNumber=0, likeNumber=81, createdTime=2017-09-26, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4c1140e4f6, moduleTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4c1140e4f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383062, encodeId=9c4b13830622d, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110822, objectId=f90d11082200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90d11082200, replyNumber=0, likeNumber=65, createdTime=2017-08-26, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90d11082200, moduleTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f90d11082200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383061, encodeId=c5c813830618a, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=66, createdTime=2017-08-26, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383060, encodeId=2eba1383060ce, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, objectType=article, longId=108173, objectId=b73d1081e30c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b73d1081e30c, replyNumber=0, likeNumber=90, createdTime=2017-08-10, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b73d1081e30c, moduleTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b73d1081e30c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383059, encodeId=84cd1383059bb, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, objectType=article, longId=101597, objectId=6d7510159e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7510159e72, replyNumber=0, likeNumber=79, createdTime=2017-06-14, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7510159e72, moduleTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7510159e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383058, encodeId=141513830583d, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, objectType=article, longId=73238, objectId=b19de323897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19de323897, replyNumber=0, likeNumber=80, createdTime=2016-07-21, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19de323897, moduleTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b19de323897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383057, encodeId=2f73138305e7d, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, objectType=article, longId=42035, objectId=067d42035e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067d42035e9, replyNumber=0, likeNumber=98, createdTime=2014-11-05, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067d42035e9, moduleTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067d42035e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383056, encodeId=225113830567a, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, objectType=article, longId=37824, objectId=30183e824a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30183e824a7, replyNumber=0, likeNumber=72, createdTime=2014-07-17, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30183e824a7, moduleTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30183e824a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383055, encodeId=fbfd13830556a, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=三种第三代EGFR-TKI药物有望将来用于NSCLC, objectType=article, longId=36428, objectId=00fd3642874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00fd3642874, replyNumber=0, likeNumber=83, createdTime=2014-06-16, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00fd3642874, moduleTitle=三种第三代EGFR-TKI药物有望将来用于NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00fd3642874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1383054, encodeId=23151383054a0, content=<a href='/topic/show?id=0c8265e2b3' target=_blank style='color:#2F92EE;'>#EGFR-TKI#</a>, objectTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, objectType=article, longId=35735, objectId=b22c35e35e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22c35e35e3, replyNumber=0, likeNumber=81, createdTime=2014-06-03, rootId=0, userName=w984445tii, userId=6732482, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22c35e35e3, moduleTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b22c35e35e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EGFR-TKI

2020-05-29

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象

2019-02-24

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！

2019-02-13

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应

2018-08-31

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究

2018-07-22

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

三代EGFR-TKI艾维替尼提交国内上市申请

2018-06-25

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

JAMA Oncol：共存突变可影响 EGFR-TKIs的疗效

2018-04-04

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

N Engl J Med：EGFR突变阳性晚期NSCLC一线治疗：奥西替尼vs标准EGFR-TKI

2017-12-28

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批

2017-11-19

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略

2017-11-11

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵

2017-11-11

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？

2017-09-26

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检

2017-08-10

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理

2017-06-14

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功

2016-07-21

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析

2014-11-05

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移

2014-07-17

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

三种第三代EGFR-TKI药物有望将来用于NSCLC

2014-06-16

w984445tii (审核中...)

前往app查看评论内容

#EGFR-TKI#

ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效

2014-06-03

科室
- - 订阅+
  - 更多科室
工具
服务